Incentives for new antibiotics: The Options Market for Antibiotics (OMA) model

Globalization and Health

Volumn 9, Issue 1, 2013, Pages

  Brogan, David M ^a,b   Mossialos, Elias ^b  

^a MAYO CLINIC   (United States)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

Antibiotic development; Antimicrobial resistance; Incentive mechanisms for new antibiotics; Options Market for Antibiotics

Indexed keywords

ANTIBIOTIC RESISTANCE; ANTIBIOTICS; DRUG DEVELOPMENT; INCENTIVE; INVESTMENT; RESEARCH AND DEVELOPMENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CONSUMER; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; HEALTH CARE NEED; INVESTMENT; MATHEMATICAL MODEL; OPTIONS MARKET FOR ANTIBIOTICS MODEL; POLICY; PRIORITY JOURNAL; PURCHASING; DRUG DEVELOPMENT; ECONOMICS; HEALTH CARE POLICY; HUMAN; MARKETING; MOTIVATION; RISK;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL; HEALTH POLICY; HUMANS; INVESTMENTS; MARKETING; MOTIVATION; RISK;

EID: 84887342969     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/1744-8603-9-58     Document Type: Article

References (43)

1. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004, 38(9):1279-1286. 10.1086/420937, 15127341.
2. Hirschler B. EU regulator calls for more antibiotic research 2010, [cited 2013 5/5/13]; Available from: http://www.reuters.com/article/2010/12/15/us-medicines-europe-idUSTRE6BE5C920101215.
3. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008, 197(8):1079-81. 10.1086/533452, 18419525.
4. ECDC/EMEA Joint Working Group The bacterial challenge: time to react, in ECDC / EMEA Joint Technical Report 2009, 1-42. Stockholm: European Centre for Disease Prevention and Control and European Medicines Agency, Available from: http://www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf, ECDC/EMEA Joint Working Group.
5. Pew Health Group The Generating Antibiotic Incentives Now Act of 2011 2011, Washington, D.C.: Pew Trust, Pew Health Group.
6. Centers for Disease Control and Prevention Antibiotic Resistance Threats in the United States. Threat Report 2013 Atlanta: Centers for Disease Control and Prevention, Report Available from: http://www.cdc.gov/drugresistance/threat-report-2013/ 2013, Centers for Disease Control and Prevention.
7. Morel CM, Mossialos E. Stoking the antibiotic pipeline. BMJ 2010, 340:c2115. 10.1136/bmj.c2115, 20483950.
8. Ridge KW, Hand K, Sharland M, Abubakar I, Livermore DM. Antimicrobial Resistance 2013, London: CMO, Annual Report of the Chief Medical Officer. Volume Two, 2011. Infections and the rise of antimicrobial resistance, Report Available from: http://www.dh.gov.uk/health/2013/03/cmo-vol2/.
9. DiMasi JA, Grabowski HG, Vernon J. R&D costs and returns by therapeutic category. Drug Inf J 2004, 38(3):211-223.
10. Spellberg B, Blaser M, , et al. Infectious Diseases Society of America (IDSA) Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011, 52(5):S397-428. Available at: http://cid.oxfordjournals.org/content/52/suppl_5/S397.full, 3738230, 21474585, Infectious Diseases Society of America (IDSA).
11. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J, Infectious Diseases Society of America (IDSA) The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008, 46(2):155-164. 10.1086/524891, 18171244, Infectious Diseases Society of America (IDSA).
12. Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) Recommendations for future collaboration between the US and EU 2011, Brussels, Available from: http://ecdc.europa.eu/en/activities/diseaseprogrammes/tatfar/pages/index.aspx, Transatlantic Taskforce on Antimicrobial Resistance (TATFAR).
13. Usdin S. Antibiotics reset: GAIN Act, FDA stance only first steps to refilling antibiotic pipeline in U.S 2012, Available from: http://www.biocentury.com/biotech-pharma-news/coverstory/2012-11-19/gain-act-fda-stance-only-first-steps-to-refilling-antibiotic-pipeline-in-us-a1.
14. Hirschler B. Analysis: Antibiotics crisis prompts rethink on risks, rewards 2013, London: Reuters, Available from: http://www.reuters.com/article/2013/03/18/us-antibiotics-idUSBRE92H0OJ20130318.
15. Wetzstein C. Antibiotic-resistant 'superbugs' alarm health care industry, in The Washington Times2013 Washington, DC, Available from: http://www.washingtontimes.com/news/2013/mar/19/antibiotic-resistant-superbugs-alarm-health-care-i/?page=all.
16. Walsh F. Antibiotics resistance 'as big a risk as terrorism' - medical chief 2013, London: BBC News, Available from: http://www.bbc.co.uk/news/health-21737844.
17. Cars O, Hogberg LD, Murray M, Nordberg O, Sivaraman S, Lundborg CS, So AD, Tomson G. Meeting the challenge of antibiotic resistance. BMJ 2008, 337:a1438. 10.1136/bmj.a1438, 18801866.
18. Moon S, MPA PD. Report of the WHO Consultative Expert Working Group on Research and Development: Financing and Coordination 2012, Washington, DC: XIX International AIDS Conference.
19. Mossialos E, Morel C, Edwards S, Berenson J, Gemmill-Toyama M, Brogan D. Policies and incentives for promoting innovation in antibiotic research 2010, Copenhagen: World Health Organization.
20. Towse A, Keuffel E, Kettler HE, Ridley DB. Drugs and vaccines for developing countries. The Oxford Handbook of The Economics of the Biopharmaceutical Industry 2011, 302-335. Oxford: Oxford University Press, Danzon P, Nicholson P.
21. Hecht R, Wilson P, Palriwala A. Improving health r&d financing for developing countries: a menu of innovative policy options. Health Aff 2009, 28(4):974-85.
22. Towse A, Kettler H. Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies. Bull World Health Organ 2005, 83(4):301-7. 2626206, 15868022.
23. Kremer M. Creating Markets for New Vaccines Part II: Design Issues. National Bureau of Economic Research Working Paper Series 2000, No. 7717 Available from: http://www.nber.org/papers/w7717.
24. Adams CP, Van Brantner, V. Estimating the cost of new drug development: is it really $802 Million?. Health Aff 2006, 25(2):420-428.
25. Berndt ER, Hurvitz JA. Vaccine advance-purchase agreements for low-income countries: practical issues. Health Aff 2005, 24(3):653-665.
26. Kaplan W, Laing R. Priority Medicines for Europe and the World 2004, Geneva: World Health Organization, Department of Essential Drugs and Medicines Policy.
27. Levine R, Kremer M, Albright A. Making Markets for Vaccines: Ideas to Action - The report of the Center for Global Development Advance Market Commitment Working Group 2005, Washington D.C.
28. Brogan D, Mossialos E. Applying the concepts of financial options to stimulate vaccine development. Nat Rev Drug Discov 2006, 5(8):641-647. 10.1038/nrd2035, 16883302.
29. Beaves R. Net present value and rate of return: implicit and explicit reinvestment assumptions. Eng Econ 1988, 33(4):275-302.
30. Remer DS, Nieto AP. A compendium and comparison of 25 project evaluation techniques. Part 1: net present value and rate of return methods. Int J Prod Econ 1995, 42(1):79-96.
31. Sosa ADJ. Antimicrobial resistance in developing countries 2010, New York: Springer.
32. Ramsey FP. A contribution to the theory of taxation. Econ J 1927, 37(145):47-61.
33. Danzon P. The economics of parallel trade. Pharmacoeconomics 1998, 13(3):293-304. 10.2165/00019053-199813030-00004, 10178655.
34. Cheng J. Optimal R&D Expenditure- A value maximization approach. Int Res J Finance Econ 2006, 5:178-185.
35. Towse A, Sharma P. Incentives for R&D for New Antimicrobial Drugs. Int J Econ Bus 2011, 18(2):331-350.
36. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 2010, 87(3):272-277. 10.1038/clpt.2009.295, 20130567.
37. Spellberg B, Sharma P, Rex JH. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nat Rev Drug Discov 2012, 11(2):168-168. 10.1038/nrd3560-c1, 22293569.
38. Innovative Medicines Initiative Innovative Medicines Initiative 2013, [cited 2013 5/6/2013]; Available from: http://www.imi.europa.eu/content/mission, Innovative Medicines Initiative.
39. Stafford N. €224 million EU antibiotics initiative launched, in Chemistry World 2012, Royal Society of Chemistry, Available from: http://www.rsc.org/chemistryworld/2012/06/224-million-eu-antibiotics-initiative-launched.
40. EFPIA IMI Launches Antimicrobial resistance (AMR) projects to revitalise antibiotic development 2013, Brussels: EFPIA, Available from: http://www.efpia.eu/mediaroom/16/78/IMI-Launches-Antimicrobial-resistance-AMR-projects-to-revitalise-antibiotic-development, EFPIA.
41. Danzon PM, Nicholson S, Pereira NS. Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances. National Bureau of Economic Research Working Paper Series, 2003. No. 9615 (also published as Danzon, Patricia M., Sean Nicholson and Nuno Sousa Pereira. "Productivity In Pharmaceutical-Biotechnology R&D: The Role Of Experience And Alliances,". J Health Econ 2005, 24(2):317-339). 10.1016/j.jhealeco.2004.09.006, 15721048.
42. Hollis A, Pogge T. Making New Medicines Accessible for All. A Report of Incentives for Global Health 2008, The Health Impact Fund.
43. Mrazek M, Mossialos E. Stimulating pharmaceutical research and development for neglected diseases. Health Policy 2003, 64(1):75-88. 10.1016/S0168-8510(02)00138-0, 12644330.